Rare diseases
Investigational molecules
Locations
16601 Blanco Road Suite 120, 78232-1938, United States
Rapamycin Holdings Inc. focuses on familial adenomatous polyposis, a hereditary condition marked by the development of numerous colorectal polyps and elevated cancer risk. Its clinical research interest centers on disease control in the gastrointestinal tract and the prevention of progression toward colorectal cancer.
The sponsor’s activity is directed toward therapeutic strategies that address inherited polyposis syndromes and their malignant transformation.
Rapamycin Holdings Inc. runs clinical trials in conditions such as Adenomatous polyposis coli, among others.
Clinical trials run by this sponsor – those enrolling participants first.
A study testing sirolimus to slow disease progression in patients with familial adenomatous polyposis
DenmarkIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
